Innoviva (INVA) Cash from Operations Growth (1y) (2011 - 2026)
Innoviva (INVA) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,440.76 Bn | 66,440.47 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 468.28 Bn | 463.49 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 122.49 Bn | 115.24 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 70.26 Bn | 61.51 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 62.88 Bn | 62.88 Bn | - | - |
| 8 | Argenx Se | 55.67 Bn | 50.48 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.37 Bn | 34.36 Bn | 959.66 Mn | 158.60% |
| 10 | Innoviva | 1.61 Bn | 1.01 Bn | 75.83 Mn | -27.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.43% |
| Sep 30, 2025 | 10.02% |
| Jun 30, 2025 | 0.81% |
| Mar 31, 2025 | 31.23% |
| Sep 30, 2024 | 20.08% |
| Jun 30, 2024 | 14.50% |
| Mar 31, 2024 | 44.24% |
| Sep 30, 2023 | -44.09% |
| Jun 30, 2023 | -51.69% |
| Mar 31, 2023 | -73.82% |
| Sep 30, 2022 | -27.35% |
| Jun 30, 2022 | -6.59% |
| Mar 31, 2022 | 16.64% |
| Sep 30, 2021 | 256.01% |
| Jun 30, 2021 | 6.04% |
| Mar 31, 2021 | 14.46% |
| Dec 31, 2020 | 27.46% |
| Sep 30, 2020 | 29.89% |
| Jun 30, 2020 | 41.24% |
| Mar 31, 2020 | -4.14% |